Value of pentraxin-3 and galectin-3 in acute coronary syndrome: A short-term prospective cohort study

Therapeutic Advances in Cardiovascular Disease

Volumn 9, Issue 5, 2015, Pages 275-284

  George, Melvin ^a   Shanmugam, Elangovan ^a   Srivatsan, Varsha ^a   Rajaram, Muthukumar ^a   Jena, Amrita ^a   Sridhar, Aruna ^a   Vasanth, Karunamoorthy ^b   Chaudhury, Minakshi ^b   Kaliappan, Ilango ^b   Ramraj, Balaji ^a  

^a SRM INSTITUTE OF SCIENCE AND TECHNOLOGY   (India)

^b SRM UNIVERSITY   (India)

Author keywords

acute coronary syndrome; all cause mortality; estimated glomerular filtration rate; galectin 3; left ventricular ejection fraction; pentraxin 3

Indexed keywords

BIOLOGICAL MARKER; GALECTIN 3; PENTRAXIN 3; C REACTIVE PROTEIN; SERUM AMYLOID P;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DISEASE ASSOCIATION; FEMALE; HEART DEATH; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; SYNDROME X; UNSTABLE ANGINA PECTORIS; BLOOD; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; METABOLISM; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PROGNOSIS;

ACUTE CORONARY SYNDROME; ADULT; ANGINA, UNSTABLE; BIOMARKERS; C-REACTIVE PROTEIN; COHORT STUDIES; FEMALE; GALECTIN 3; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; PROSPECTIVE STUDIES; SERUM AMYLOID P-COMPONENT; VENTRICULAR FUNCTION, LEFT;

EID: 84944032248     PISSN: 17539447     EISSN: 17539455     Source Type: Journal    
DOI: 10.1177/1753944715578405     Document Type: Article

References (42)

1. Anand I. Rector T. Kuskowski M. Adourian A. Muntendam P. Cohn J. (2013) Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur J Heart Fail 15: 511–518.
2. Arroyo-Espliguero R. Avanzas P. Cosín-Sales J. Aldama G. Pizzi C. Kaski J. (2004) C-reactive protein elevation and disease activity in patients with coronary artery disease. Eur Heart J 25: 401–408.
3. Atkinson A. Colburn W. DeGruttola V. DeMets D. Downing G. Hoth D. et al. (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69: 89–95.
4. Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69: 89–95.
5. Breviario F. d’Aniello E. Golay J. Peri G. Bottazzi B. Bairoch A. et al. (1992) Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component. J Biol Chem 267: 22190–22197.
6. Bulatao R. Stephens P. (1992) Global Estimates and Projections of Mortality by Cause, 1970–2015. Washington, DC: World Bank.
7. Dagher S. Wang J. Patterson R. (1995) Identification of galectin-3 as a factor in pre-mRNA splicing. Proc Natl Acad Sci U S A 92: 1213–1217.
8. de Boer R. Yu L. van Veldhuisen D. (2010) Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep 7: 1–8.
9. Eggers K. Armstrong P. Califf R. Johnston N. Simoons M. Venge P. et al. (2013) Clinical and prognostic implications of circulating pentraxin 3 levels in non ST-elevation acute coronary syndrome. Clin Biochem 46: 1655–1659.
10. Go A. Mozaffarian D. Roger V. Benjamin E. Berry J. Blaha M. et al. (2014) Executive summary: heart disease and stroke statistics – 2014 update: a report from the American Heart Association. Circulation 129: 399–410.
11. Gopal D. Kommineni M. Ayalon N. Koelbl C. Ayalon R. Biolo A. et al. (2012) Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure. J Am Heart Assoc 1: e000760.
12. Grandin E. Jarolim P. Murphy S. Ritterova L. Cannon C. Braunwald E. et al. (2012) Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22. Clin Chem 58: 267–273.
13. Habib S. Kurdi M. Al Aseri Z. Suriya M. (2011) CRP levels are higher in patients with ST elevation than non-ST elevation acute coronary syndrome. Arq Bras Cardiol 96: 13–17.
14. Hughes R. (2001) Galectins as modulators of cell adhesion. Biochimie 83: 667–676.
15. Inoue K. Kodama T. Daida H. (2012) Pentraxin 3: a novel biomarker for inflammatory cardiovascular disease. Int J Vasc Med 2012: e657025.
16. Kanbay M. Ikizek M. Solak Y. Selcoki Y. Uysal S. Armutcu F. et al. (2011) Uric acid and pentraxin-3 levels are independently associated with coronary artery disease risk in patients with stage 2 and 3 kidney disease. Am J Nephrol 33: 325–331.
17. Kunes P. Holubcova Z. Kolackova M. Krejsek J. (2012) Pentraxin 3(PTX 3): an endogenous modulator of the inflammatory response. Mediators Inflamm 2012: e920517.
18. Lee D. Jeon H. You J. Park M. Lee S. Kim S. et al. (2010) Pentraxin 3 as a novel marker predicting congestive heart failure in subjects with acute coronary syndrome. Korean Circ J 40: 370–376.
19. Lee G. Goodman A. Lee T. Vilcek J. (1994) Relationship of TSG-14 protein to the pentraxin family of major acute phase proteins. J Immunol 153: 3700–3707.
20. Market Research Reports (2014) EpiCast Report: Acute coronary syndrome (ACS) - epidemiology forecast to 2023. Lewes, DE, USA and Bangalore, India: Market Research Reports Inc.
21. Matsubara J. Sugiyama S. Nozaki T. Sugamura K. Konishi M. Ohba K. et al. (2011) Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction. J Am Coll Cardiol 57: 861–869.
22. Matsui S. Ishii J. Kitagawa F. Kuno A. Hattori K. Ishikawa M. et al. (2010) Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction. Atherosclerosis 210: 220–225.
23. Maugeri N. Rovere-Querini P. Slavich M. Coppi G. Doni A. Bottazzi B. et al. (2011) Early and transient release of leukocyte pentraxin 3 during acute myocardial infarction. J Immunol 187: 970–979.
24. Mayr A. Klug G. Mair J. Streil K. Harrasser B. Feistritzer H. et al. (2013) Galectin-3: relation to infarct scar and left ventricular function after myocardial infarction. Int J Cardiol 163:335–337.
25. Meijers W. van der Velde A. Ruifrok W. Schroten N. Dokter M. Damman K. et al. (2014) Renal handling of galectin-3 in the general population, chronic heart failure, and hemodialysis. J Am Heart Assoc 3: e000962.
26. Milting H. Ellinghaus P. Seewald M. Cakar H. Bohms B. Kassner A. et al. (2008) Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J Heart Lung Transplant 27: 589–596.
27. Motiwala S. Szymonifka J. Belcher A. Weiner R. Baggish A. Sluss P. et al. (2013) Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. Eur J Heart Fail 15: 1157–1163.
28. Nagesh C. Roy A. (2010) Role of biomarkers in risk stratification of acute coronary syndrome. Indian J Med Res 132: 627–633.
29. Parlak A. Aydoğan U. Iyisoy A. Dikililer M. Kut A. Cakır E. et al. (2012) Elevated pentraxin-3 levels are related to blood pressure levels in hypertensive patients: an observational study. Anadolu Kardiyol Derg 12: 298–304.
30. Peri G. Introna M. Corradi D. Iacuitti G. Signorini S. Avanzini F. et al. (2000) PTX3, a prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 102: 636–641.
31. Salio M. Chimenti S. de Angelis N. Molla F. Maina V. Nebuloni M. et al. (2008) Cardioprotective function of the long pentraxin PTX 3 in acute myocardial infarction. Circulation 117: 1055–1064.
32. Sato S. Hughes R. (1994) Regulation of secretion and surface expression of Mac-2, a galactoside-binding protein of macrophages. J Biol Chem 269: 4424–4430.
33. Sharma U. Pokharel S. van Brakel T. van Berlo J. Cleutjens J. Schroen B. et al. (2004) Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 110: 3121–3128.
34. Szadkowska I. Wlazel R. Migala M. Bajon-Laskowska K. Szadkowski K. Zielińska M. et al. (2013) The association between galectin-3 and occurrence of reinfarction early after first myocardial infarction treated invasively. Biomarkers 18: 655–659.
35. Tsai T. Sung P. Chang L. Sun C. Yeh K. Chung S. et al. (2012) Value and level of galectin-3 in acute myocardial infarction patients undergoing primary percutaneous coronary intervention.J Atheroscler Thromb 19: 1073–1082.
36. Ustündağ M. Orak M. Güloğlu C. Sayhan M. Alyan O. Kale E. (2011) Comparative diagnostic accuracy of serum levels of neutrophil activating peptide-2 and pentraxin-3 versus troponin-I in acute coronary syndrome. Anadolu Kardiyol Derg 11: 588–594.
37. van Kimmenade R. Januzzi J. Ellinor P. Sharma U. Bakker J. Low A. et al. (2006) Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 48: 1217–1224.
38. Weir R. Petrie C. Murphy C. Clements S. Steedman T. Miller A. et al. (2013) Galectin-3 and cardiac function in survivors of acute myocardial infarction. Circ Heart Fail 6: 492–498.
39. Yin Q. Shi B. Dong L. Bi L. (2014) Comparative study of galectin-3 and B-type natriuretic peptide as biomarkers for the diagnosis of heart failure. J Geriatr Cardiol 11: 79–82.
40. Xavier D. Pais P. Devereaux P. Xie C. Prabhakaran D. Reddy K. et al. (2008) Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data. Lancet 371: 1435–1442.
41. Zairis M. Lyras A. Bibis G. Patsourakos N. Makrygiannis S. Kardoulas A. et al. (2005) Association of inflammatory biomarkers and cardiac troponin I with multifocal activation of coronary artery tree in the setting of non-ST-elevation acute myocardial infarction. Atherosclerosis 182:161–167.
42. Zouridakis E. Avanzas P. Arroyo-Espliguero R. Fredericks S. Kaski J. (2004) Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris. Circulation 110: 1747–1753.